DrugId:  1
1. Name:  Lorvotuzumab mertansine
2. Groups:  Investigational
3. Description:  Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
4. Indication:  Not Available
DrugId:  2
1. Name:  Platinum
2. Groups:  Investigational
3. Description:  Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Primary Cancer, Non Small Cell Lung Cancer, and Primary Peritoneal Carcinoma, among others.
4. Indication:  Not Available
DrugId:  3
1. Name:  Naptumomab Estafenatox
2. Groups:  Investigational
3. Description:  Naptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.
4. Indication:  Not Available
DrugId:  4
1. Name:  Selumetinib
2. Groups:  Investigational
3. Description:  Selumetinib is under investigation for the treatment of Carcinoma, Thymic, Non-Small Cell Lung Cancer, and Carcinoma, Small Cell Lung. AZD6244 has been investigated for the treatment and basic science of Melanoma, Solid Tumours, Breast Cancer, Non Small Cell Lung Cancer, and Non Small Cell Lung Carcinoma, among others.
4. Indication:  Not Available
DrugId:  5
1. Name:  Isoquercetin
2. Groups:  Investigational
3. Description:  Isoquercetin has been used in trials studying the treatment of Kidney Cancer, Renal cell carcinoma, Advanced Renal Cell Carcinoma, Thromboembolism of Vein in Pancreatic Cancer, and Thromboembolism of Vein VTE in Colorectal Cancer, among others.
4. Indication:  Not Available
DrugId:  6
1. Name:  Apitolisib
2. Groups:  Investigational
3. Description:  Apitolisib has been used in trials studying the treatment of Solid Cancers, Breast Cancer, Prostate Cancer, Renal Cell Carcinoma, and Endometrial Carcinoma, among others.
4. Indication:  Not Available
DrugId:  7
1. Name:  ABT-869
2. Groups:  Investigational
3. Description:  ABT-869 is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels that supply the tumor with oxygen and nutrients and by inhibiting key angiogenic signaling pathways. ABT-869 is intended for the treatment of hematologic malignancies and the solid tumors.
4. Indication:  Investigated for use/treatment in leukemia (myeloid), myelodysplastic syndrome, and solid tumors.
DrugId:  8
1. Name:  Roniciclib
2. Groups:  Investigational
3. Description:  Roniciclib has been investigated for the treatment of Small Cell Lung Carcinoma.
4. Indication:  Not Available
DrugId:  9
1. Name:  NVP-LEQ-506
2. Groups:  Investigational
3. Description:  LEQ506 has been used in trials studying the treatment of Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma, and Locally Advanced or Metastatic Basal Cell Carcinoma.
4. Indication:  Not Available
DrugId:  10
1. Name:  Lapachone
2. Groups:  Investigational
3. Description:  Lapachone has been used in trials studying the treatment of Cancer, Carcinoma, Advanced Solid Tumors, Head and Neck Neoplasms, and Carcinoma, Squamous Cell.
4. Indication:  Not Available
DrugId:  11
1. Name:  Vismodegib
2. Groups:  Approved, Investigational
3. Description:  Vismodegib inhibits the hedgehog signalling pathway and is indicated for treatment of adult basal cell carcinoma. FDA approved on Jan 30, 2012. 
4. Indication:  Vismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation.
DrugId:  12
1. Name:  Volociximab
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.
DrugId:  13
1. Name:  Imiquimod
2. Groups:  Approved, Investigational
3. Description:  Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
4. Indication:  For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
DrugId:  14
1. Name:  Etaracizumab
2. Groups:  Investigational
3. Description:  Etaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.
4. Indication:  Not Available
DrugId:  15
1. Name:  WX-G250
2. Groups:  Investigational
3. Description:  WX-G250 is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC). 
4. Indication:  Investigated for use/treatment in gall bladder cancer and renal cell carcinoma.
DrugId:  16
1. Name:  CC-223
2. Groups:  Investigational
3. Description:  CC-223 has been used in trials studying the treatment and basic science of Multiple Myeloma, Glioblastoma Multiforme, HepatoCellular Carcinoma, Non-small Cell Lung Cancer, and Diffuse Large B-Cell Lymphoma, among others.
4. Indication:  Not Available
DrugId:  17
1. Name:  Endostar
2. Groups:  Investigational
3. Description:  Endostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer.
4. Indication:  Not Available
DrugId:  18
1. Name:  Monalizumab
2. Groups:  Investigational
3. Description:  Monalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.
4. Indication:  Not Available
DrugId:  19
1. Name:  Emibetuzumab
2. Groups:  Investigational
3. Description:  Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
4. Indication:  Not Available
DrugId:  20
1. Name:  Cabozantinib
2. Groups:  Approved, Investigational
3. Description:  Cabozantinib was approved in 2012 and is a non-specific tyrosine kinase inhibitor. It is marketed as Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. It's label includes a black box warning of gastrointestinal perforations, fistulas, and hemorrhage. The FDA approved cabozantinib as Cabometyx for patients with advanced renal cell carcinoma in April 2016.
4. Indication:  For the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
DrugId:  21
1. Name:  Infigratinib
2. Groups:  Investigational
3. Description:  Infigratinib is under investigation for the treatment of Head and Neck Squamous Cell Carcinoma.
4. Indication:  Not Available
DrugId:  22
1. Name:  LY-2584702
2. Groups:  Investigational
3. Description:  LY2584702 has been used in trials studying the treatment of Cancer, Advanced Cancer, Renal Cell Carcinoma, Metastases, Neoplasm, and Neuroendocrine Tumors, among others.
4. Indication:  Not Available
DrugId:  23
1. Name:  Nimorazole
2. Groups:  Investigational
3. Description:  Nimorazole has been used in trials studying the treatment of Hypoxia, Radiotherapy, Hypoxic Modification, Gene Profile, Gene Signature, and Head and Neck Squamous Cell Carcinoma, among others.
4. Indication:  Not Available
DrugId:  24
1. Name:  Tecemotide
2. Groups:  Investigational
3. Description:  Tecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung.
4. Indication:  Not Available
DrugId:  25
1. Name:  Biomed 101
2. Groups:  Investigational
3. Description:  Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid. Biomed 101 binds to the leukotriene B4 receptor, but does not affect interleukin-2 antitumor activity.
4. Indication:  Investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma.
